HIMSMonday, 22 Jun 2026
Yale study targets asynchronous prescribing and the Medicare GLP-1 Bridge pilot starts on 1 Jul…
Ahead of the FDA PCAC on 23-24 Jul, two policy and regulatory signals pointing the same way are adding public pressure on HIMS's model of remote, asynchronous prescribing. It is a narrative headwind, not a fundamental turning point, but it raises the tail risk around the meeting.
Read more
The current share price of $35.47 is well above the sell-side consensus average of $28-29. With policy headwinds and a stretched valuation, the risk/reward is unfavourable.
Key evidence
- A new Yale study finds that about 2/3 of online GLP-1 prescriptions are written without any substantive doctor-patient communication beforehand, and that some platforms replace full consultations with quick, non-personalised prescribing (reported by HCPLive on 22 Jun)
- The study goes to the heart of HIMS's asynchronous consultation model: fill in a form, get an asynchronous review by algorithm or clinician, then receive a prescription, with no mandatory video visit
- On 16 Jun the FDA sent warning letters to 25 telehealth companies (confirmed by Reuters). Together with the Yale study, that makes a run of policy signals.
- The CMS Medicare GLP-1 Bridge pilot starts on 1 Jul and runs to the end of 2027. Eligible Part D enrollees can get some branded GLP-1s for about $50 a month.
- HIMS sells cash-pay subscriptions ($129-299 a month for compounded or branded GLP-1s). Genuine branded drugs at $50 a month through the government weaken its value-for-money story for people over 65.
- HIMS's core customers are self-paying people under 65, so direct overlap with Medicare is limited and the short-term impact is small
Show 2 more
- Closed Friday at $35.47. No new analyst rating or target changes, and the latest 8-K filed with the SEC is still the one from 15 Jun.
- The sell-side consensus average is $28-29, and the share price is now well above consensus
Catalysts to watch
- Launch of the CMS Medicare GLP-1 Bridge pilot on 1 Jul
- FDA PCAC advisory meeting on peptides, 23-24 Jul (the real binary event)
Risks
- Regulators and plaintiffs' lawyers will use the Yale study as ammunition to attack the quality of asynchronous prescribing
- The FDA's 25 warning letters, the Yale study and the Medicare pilot add up to a triple blow on the policy narrative
- Tail risk is rising for the 23 Jul PCAC meeting, as regulators keep tightening on aggressive remote prescribing
- A stretched valuation: $35.47 against a sell-side average of $28-29 leaves plenty of room to fall
- Better access to genuine branded drugs squeezes the policy room for compounded and grey-market supply
Sources (3)
- HCPLive report on the Yale study (22 Jun)
- Reuters on the FDA's 25 warning letters (16 Jun)
- The Hill; CMS official FAQ 'Information for Pharmacies' (21 Jun)
A brief is a lead for our research, not a verified conclusion or advice.